PRN 201, PRN 222, and PRN 211 are all bi-specific ADCs based on ArtBody technology and are being developed for solid cancer indications such as colorectal cancer and lung cancer. Currently, process development and non-clinical efficacy testing for PRN 201 are in progress, and PRN 222 is also in the research stage to confirm candidate substances. In addition to the development of bi-specific ADCs, new candidates are also being developed that incorporate platforms such as ICE (immune cell engager) and CAR (chimeric antigen receptor).
